Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a research report report published on Wednesday.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Separately, Ladenburg Thalmann Financial Services assumed coverage on Krystal Biotech in a research report on Wednesday, October 18th. They issued a buy rating and a $23.00 target price for the company.
Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 13th. The company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.52). research analysts expect that Krystal Biotech will post -1.85 EPS for the current year.
An institutional investor recently bought a new position in Krystal Biotech stock. Highbridge Capital Management LLC bought a new position in Krystal Biotech Inc (NASDAQ:KRYS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 300,000 shares of the company’s stock, valued at approximately $2,991,000. Highbridge Capital Management LLC owned 3.11% of Krystal Biotech as of its most recent SEC filing. Institutional investors own 30.72% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/07/krystal-biotech-krys-upgraded-to-hold-at-zacks-investment-research.html.
About Krystal Biotech
Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.